Risperidone for Substance Dependent Psychotic Patients

被引:4
|
作者
Poling, James
Kosten, Thomas R.
机构
[1] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA
[2] VISN 1 Mental Illness Res Educ & Clin Ctr, West Haven, CT USA
来源
关键词
risperidone; substance use disorders; schizophrenia; cannabis; stimulants;
D O I
10.1097/00132576-200503000-00001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: This study examined urine toxicology results at a single VA clinic in psychotic veterans with substance use disorders before and after switching to risperidone. Methods: In FY1995-2000, 104 psychotic veterans with substance use disorders (SUD) switched to risperidone (0.5-4 mg) and had urine toxicologies (avg 18) documenting opiate, cocaine, or marijuana use for at least 3 months before and after switching. Results: The rate of illicit urines was significantly higher before than after switching to risperidone (38% vs. 29%) (cocaine 19% to 15%; cannabis 13% to 10%). Conclusions: Urine toxicologies in a sample of veterans showed that risperidone was associated with a modest reduction in a range of illicit drugs over a period of 3 months before and after a medication switch.
引用
收藏
页码:1 / 3
页数:3
相关论文
共 50 条
  • [31] Neuropsychology of comorbid psychotic and substance use disorder patients
    Sheng, X.
    Binks, I. I. I. S. W.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2008, 23 (06) : 654 - 654
  • [32] Substance use and sleep problems in patients with psychotic disorders
    Cederlof, E. V.
    Holm, M.
    Ahti, J.
    Lahteenvuo, M.
    Suvisaari, J.
    Lonnqvist, J.
    Kieseppa, T.
    Kampman, O.
    Hakkinen, K.
    Palotie, A.
    Tiihonen, J.
    Isometsa, E.
    Niemela, S.
    Paunio, T.
    JOURNAL OF SLEEP RESEARCH, 2022, 31
  • [33] Stable elderly patients with psychotic disorders improve with long-acting risperidone
    Eerdekens, M
    Lasser, R
    Bossie, C
    Zhu, Y
    Gharabawi, G
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 282 - 282
  • [34] Risperidone long acting injectable in elderly psychotic patients: assessment of tolerability and efficacy
    Simpson, S
    Heise, M
    Konstantinos, K
    Glue, P
    Medori, R
    Kissling, W
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S513 - S513
  • [35] Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders
    Bocharov, A. V.
    Kondakova, V. E.
    Tuleninov, E. S.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (06) : 25 - 31
  • [36] Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome
    Müller-Siecheneder, F
    Müller, MJ
    Hillert, A
    Szegedi, A
    Wetzel, H
    Benkert, O
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (02) : 111 - 120
  • [37] Long-term efficacy, safety, and tolerability of risperidone in elderly psychotic patients
    Chanlam, A
    Davidson, M
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S62 - S62
  • [38] Risperidone plus benzodiazepines as an effective and well tolerated treatment for acute psychotic patients
    Baciu, D
    Braendle, D
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S265 - S266
  • [39] Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients
    Dollfus, S
    Olivier, W
    Chabot, B
    Déal, C
    Perrin, E
    SCHIZOPHRENIA RESEARCH, 2005, 78 (2-3) : 157 - 159
  • [40] Risperidone for non-psychotic disorders in paediatric patients: which child is to benefit?
    Hoekstra, Pieter J.
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2014, 56 (10): : 919 - 920